Big changes in guidelines will lead to debate about managing heart failure with reduced ejection fraction (HFrEF).
Now Entresto (sacubitril/valsartan) is preferred INSTEAD of an ACEI or ARB when possible...since it prevents hospitalization or CV death in about 1 in 21 patients versus an ACEI.
Guidelines also suggest “QUAD therapy”...adding an SGLT2 inhibitor (Farxiga, etc) to triple therapy, regardless of diabetes. This prevents hospitalization or CV death in about 1 in 20 patients.
But med adherence in clinical trials is much higher than in real-world patients. Plus Entresto or an SGLT2 inhibitor each costs about $600/month.
Continue to focus on optimizing traditional triple therapy first...this can cost under $30/month. And less than 1% of patients with HFrEF are on triple therapy at target doses.
Then use shared decision-making to determine whether this new guidance is practical for your patient.
If patients still have heart failure symptoms, consider switching from an ACEI or ARB to Entresto. But keep in mind, Entresto is taken bid...and causes low BP in 1 in 21 patients.
Ensure patients wait at least 36 hours after stopping an ACEI if switching to Entresto...to reduce risk of angioedema.
If symptomatic patients are already on optimized triple therapy with Entresto...or also have type 2 diabetes...think about adding an SGLT2 inhibitor. Benefits are likely a class effect.
But weigh SGLT2 inhibitor downsides...genitourinary infections, dehydration, etc. Consider lowering diuretic doses when starting due to risk of hypovolemia and acute kidney injury.
Expect prior auths or high co-pays with these costly Rxs. Review our Guide for Helping Patients Afford Their Meds for ways to assist...such as whittling duplicate or unneeded meds.
See our resource, Improving Heart Failure Care, for patient education tools, strategies to improve adherence, and more.
- J Am Coll Cardiol. 2022 Mar 24. doi: 10.1016/j.jacc.2021.12.012
- N Engl J Med. 2020 Oct 8;383(15):1413-1424
- N Engl J Med. 2014 Sep 11;371(11):993-1004
- N Engl J Med. 2019 Nov 21;381(21):1995-2008
- Medication pricing by Elsevier, accessed Apr 2022